Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, th...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2006-03, Vol.42 (5), p.657-668 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 668 |
|---|---|
| container_issue | 5 |
| container_start_page | 657 |
| container_title | Clinical infectious diseases |
| container_volume | 42 |
| creator | Talbot, George H. Bradley, John Edwards, John E. Gilbert, David Scheld, Michael Bartlett, John G. |
| description | The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline. |
| doi_str_mv | 10.1086/499819 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70721242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4484678</jstor_id><oup_id>10.1086/499819</oup_id><sourcerecordid>4484678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-e44354f7d25211ac6be7f6ecc8f8dd5372663638985467a8a9578d81c23343913</originalsourceid><addsrcrecordid>eNp10d1q1EAUB_Agiq1Vn0BkFOpdNJP57l3adW2h-IFbkN4Ms5MTnW2SiTNJaZ_E13XaLF0QvJoD58d_Dudk2UtcvMeF5B-oUhKrR9k-ZkTknCn8ONUFkzmVRO5lz2LcFAXGsmBPsz3MKRUY4_3sz7Gp0fH0M6LPADVahFQeoapHF0NtRkC-R-MvQAu4htYPHfQj-uoGaF0PqAm-u-9W_eg6Z4NfO9Oi6tq41qxd68ZbtDLxCi19sCmqucdnfQN2dH6KaOEimAgRfffWQdKJVB0EZ83z7Elj2ggvtu9BdrH8uDo5zc-_fDo7qc5zS7Eac6CUMNqIumQlxsbyNYiGg7WykXWdVlFyTjiRSjLKhZFGMSFriW1JCCUKk4Ps3Zw7BP97gjjqzkULbWt6SCNqUYgSl7RM8O0_cOOn0KfZdImV4pJztUtLu4gxQKOH4DoTbjUu9N2d9HynBF9v06Z1B_WObQ-TwOEWmGhN2wTTWxd3TqQLc3nn3szOT8P_P3s1m00cfXhQlMq0E5na-dx2cYSbh7YJV5oLIpg-_XGpV5fLb4yTpabkL_R5uxk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219968669</pqid></control><display><type>article</type><title>Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Talbot, George H. ; Bradley, John ; Edwards, John E. ; Gilbert, David ; Scheld, Michael ; Bartlett, John G.</creator><creatorcontrib>Talbot, George H. ; Bradley, John ; Edwards, John E. ; Gilbert, David ; Scheld, Michael ; Bartlett, John G. ; Antimicrobial Availability Task Force of the Infectious Diseases Society of America</creatorcontrib><description>The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/499819</identifier><identifier>PMID: 16447111</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acinetobacter ; Anti-Bacterial Agents ; Antibacterials ; Antibiotics ; Antimicrobials ; Bacteria ; Biological and medical sciences ; Business structures ; Communicable Diseases, Emerging - drug therapy ; Drug Approval ; Drugs ; Drugs, Investigational ; Humans ; Infections ; Infectious diseases ; Medical sciences ; Pathogens ; Patients ; Pharmaceutical industry ; Pipelines ; Public Health ; R&D ; Research & development ; Staphylococcus aureus ; Task forces ; Viewpoint</subject><ispartof>Clinical infectious diseases, 2006-03, Vol.42 (5), p.657-668</ispartof><rights>Copyright 2006 The Infectious Diseases Society of America</rights><rights>2006 by the Infectious Diseases Society of America 2006</rights><rights>2006 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Mar 1, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-e44354f7d25211ac6be7f6ecc8f8dd5372663638985467a8a9578d81c23343913</citedby><cites>FETCH-LOGICAL-c419t-e44354f7d25211ac6be7f6ecc8f8dd5372663638985467a8a9578d81c23343913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4484678$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4484678$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,777,781,800,27905,27906,57998,58231</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17591681$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16447111$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Talbot, George H.</creatorcontrib><creatorcontrib>Bradley, John</creatorcontrib><creatorcontrib>Edwards, John E.</creatorcontrib><creatorcontrib>Gilbert, David</creatorcontrib><creatorcontrib>Scheld, Michael</creatorcontrib><creatorcontrib>Bartlett, John G.</creatorcontrib><creatorcontrib>Antimicrobial Availability Task Force of the Infectious Diseases Society of America</creatorcontrib><title>Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.</description><subject>Acinetobacter</subject><subject>Anti-Bacterial Agents</subject><subject>Antibacterials</subject><subject>Antibiotics</subject><subject>Antimicrobials</subject><subject>Bacteria</subject><subject>Biological and medical sciences</subject><subject>Business structures</subject><subject>Communicable Diseases, Emerging - drug therapy</subject><subject>Drug Approval</subject><subject>Drugs</subject><subject>Drugs, Investigational</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pipelines</subject><subject>Public Health</subject><subject>R&D</subject><subject>Research & development</subject><subject>Staphylococcus aureus</subject><subject>Task forces</subject><subject>Viewpoint</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10d1q1EAUB_Agiq1Vn0BkFOpdNJP57l3adW2h-IFbkN4Ms5MTnW2SiTNJaZ_E13XaLF0QvJoD58d_Dudk2UtcvMeF5B-oUhKrR9k-ZkTknCn8ONUFkzmVRO5lz2LcFAXGsmBPsz3MKRUY4_3sz7Gp0fH0M6LPADVahFQeoapHF0NtRkC-R-MvQAu4htYPHfQj-uoGaF0PqAm-u-9W_eg6Z4NfO9Oi6tq41qxd68ZbtDLxCi19sCmqucdnfQN2dH6KaOEimAgRfffWQdKJVB0EZ83z7Elj2ggvtu9BdrH8uDo5zc-_fDo7qc5zS7Eac6CUMNqIumQlxsbyNYiGg7WykXWdVlFyTjiRSjLKhZFGMSFriW1JCCUKk4Ps3Zw7BP97gjjqzkULbWt6SCNqUYgSl7RM8O0_cOOn0KfZdImV4pJztUtLu4gxQKOH4DoTbjUu9N2d9HynBF9v06Z1B_WObQ-TwOEWmGhN2wTTWxd3TqQLc3nn3szOT8P_P3s1m00cfXhQlMq0E5na-dx2cYSbh7YJV5oLIpg-_XGpV5fLb4yTpabkL_R5uxk</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Talbot, George H.</creator><creator>Bradley, John</creator><creator>Edwards, John E.</creator><creator>Gilbert, David</creator><creator>Scheld, Michael</creator><creator>Bartlett, John G.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20060301</creationdate><title>Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America</title><author>Talbot, George H. ; Bradley, John ; Edwards, John E. ; Gilbert, David ; Scheld, Michael ; Bartlett, John G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-e44354f7d25211ac6be7f6ecc8f8dd5372663638985467a8a9578d81c23343913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acinetobacter</topic><topic>Anti-Bacterial Agents</topic><topic>Antibacterials</topic><topic>Antibiotics</topic><topic>Antimicrobials</topic><topic>Bacteria</topic><topic>Biological and medical sciences</topic><topic>Business structures</topic><topic>Communicable Diseases, Emerging - drug therapy</topic><topic>Drug Approval</topic><topic>Drugs</topic><topic>Drugs, Investigational</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pipelines</topic><topic>Public Health</topic><topic>R&D</topic><topic>Research & development</topic><topic>Staphylococcus aureus</topic><topic>Task forces</topic><topic>Viewpoint</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Talbot, George H.</creatorcontrib><creatorcontrib>Bradley, John</creatorcontrib><creatorcontrib>Edwards, John E.</creatorcontrib><creatorcontrib>Gilbert, David</creatorcontrib><creatorcontrib>Scheld, Michael</creatorcontrib><creatorcontrib>Bartlett, John G.</creatorcontrib><creatorcontrib>Antimicrobial Availability Task Force of the Infectious Diseases Society of America</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Talbot, George H.</au><au>Bradley, John</au><au>Edwards, John E.</au><au>Gilbert, David</au><au>Scheld, Michael</au><au>Bartlett, John G.</au><aucorp>Antimicrobial Availability Task Force of the Infectious Diseases Society of America</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>42</volume><issue>5</issue><spage>657</spage><epage>668</epage><pages>657-668</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>16447111</pmid><doi>10.1086/499819</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2006-03, Vol.42 (5), p.657-668 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70721242 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Acinetobacter Anti-Bacterial Agents Antibacterials Antibiotics Antimicrobials Bacteria Biological and medical sciences Business structures Communicable Diseases, Emerging - drug therapy Drug Approval Drugs Drugs, Investigational Humans Infections Infectious diseases Medical sciences Pathogens Patients Pharmaceutical industry Pipelines Public Health R&D Research & development Staphylococcus aureus Task forces Viewpoint |
| title | Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A43%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bad%20Bugs%20Need%20Drugs:%20An%20Update%20on%20the%20Development%20Pipeline%20from%20the%20Antimicrobial%20Availability%20Task%20Force%20of%20the%20Infectious%20Diseases%20Society%20of%20America&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Talbot,%20George%20H.&rft.aucorp=Antimicrobial%20Availability%20Task%20Force%20of%20the%20Infectious%20Diseases%20Society%20of%20America&rft.date=2006-03-01&rft.volume=42&rft.issue=5&rft.spage=657&rft.epage=668&rft.pages=657-668&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/499819&rft_dat=%3Cjstor_proqu%3E4484678%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219968669&rft_id=info:pmid/16447111&rft_jstor_id=4484678&rft_oup_id=10.1086/499819&rfr_iscdi=true |